TSTori L. Schaefer

Tori L. Schaefer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tori L. Schaefer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Charles V. Vorhees

    University of Cincinnati College of Medicine, Department of Pediatrics and Cincinnati Children's Hospital Medical Center, Division of Neurology, Cincinnati, OH 45229, USA

    5 shared publications
  • Michael T. Williams

    University of Cincinnati College of Medicine, Department of Pediatrics and Cincinnati Children's Hospital Medical Center, Division of Neurology, Cincinnati, OH 45229, USA

    5 shared publications
  • Devon L. Graham

    Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL, 32306, USA; Institute for Pediatric Rare Diseases, Florida State University College of Medicine, Tallahassee, FL, 32306, USA

    4 shared publications
  • Matthew R. Skelton

    Department of Pediatrics, University of Cincinnati College of Medicine and Division of Neurology, Cincinnati Children’s Research Foundation

    4 shared publications
  • Amanda A. Braun

    Division of Neurology, Cincinnati Children's Research Foundation, Cincinnati, OH, United States; University of Cincinnati College of Medicine, Cincinnati, OH 45229, United States

    3 shared publications
  • Peter H. Tang

    Departments of Pediatrics, Pathology and Laboratory Medicine, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA

    2 shared publications

Latest Publications

  • Open Access

    Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety

    by Tori L. Schaefer, Matthew H. Davenport, Lindsay M. Grainger, Chandler K. Robinson, Anthony T. Earnheart, Melinda S. Stegman, Anna L. Lang, Amy A. Ashworth, Gemma Molinaro, Kimberly M. Huber, et al.

    Fragile X Syndrome (FXS) occurs as a result of a silenced fragile X mental retardation 1 gene (FMR1) and subsequent loss of fragile X mental retardation protein (FMRP) expression. Loss of FMRP alters excitatory/inhibitory signaling balance, leading to increased neuronal hyperexcitability and altered behavior. Acamprosate (the calcium salt of N-acetylhomotaurinate), a drug FDA-approved for relapse prevention in the treatment of alcohol dependence in adults, is a novel agent with multiple mechanisms that may be beneficial for people with FXS. There are questions regarding the neuroactive effects of acamprosate and the significance of the molecule’s calcium moiety. Therefore, the electrophysiological, cellular, molecular, and behavioral effects of acamprosate were assessed in the Fmr1 -/y (knock out; KO) mouse model of FXS controlling for the calcium salt in several experiments. Fmr1 KO mice and their wild-type (WT) littermates were utilized to assess acamprosate treatment on cortical UP state parameters, dendritic spine density, and seizure susceptibility. Brain extracellular-signal regulated kinase 1/2 (ERK1/2) activation was used to investigate this signaling molecule as a potential biomarker for treatment response. Additional adult mice were used to assess chronic acamprosate treatment and any potential effects of the calcium moiety using CaCl2 treatment on behavior and nuclear ERK1/2 activation. Acamprosate attenuated prolonged cortical UP state duration, decreased elevated ERK1/2 activation in brain tissue, and reduced nuclear ERK1/2 activation in the dentate gyrus in KO mice. Acamprosate treatment modified behavior in anxiety and locomotor tests in Fmr1 KO mice in which control-treated KO mice were shown to deviate from control-treated WT mice. Mice treated with CaCl2 were not different from saline-treated mice in the adult behavior battery or nuclear ERK1/2 activation. These data indicate that acamprosate, and not calcium, improves function reminiscent of reduced anxiety-like behavior and hyperactivity in Fmr1 KO mice and that acamprosate attenuates select electrophysiological and molecular dysregulation that may play a role in the pathophysiology of FXS. Differences between control-treated KO and WT mice were not evident in a recognition memory test or in examination of acoustic startle response/prepulse inhibition which impeded conclusions from being made about the treatment effects of acamprosate in these instances.


  • Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism

    by Craig A. Erickson, Balmiki Ray, Logan K. Wink, Baindu L. Bayon, Ernest V. Pedapati, Rebecca Shaffer, Tori L. Schaefer, Debomoy K. Lahiri


  • Developmental stress and lead (Pb): Effects of maternal separation and/or Pb on corticosterone, monoamines, and blood Pb in rats

    by Robyn M. Amos-Kroohs, Devon L. Graham, Curtis E. Grace, Amanda A. Braun, Tori L. Schaefer, Matthew R. Skelton, Charles V. Vorhees, Michael T. Williams


  • Open Access

    Effects of developmental manganese, stress, and the combination of both on monoamines, growth, and corticosterone

    by Charles V. Vorhees, Devon L. Graham, Robyn M. Amos-Kroohs, Amanda A. Braun, Curtis E. Grace, Tori L. Schaefer, Matthew R. Skelton, Keith M. Erikson, Michael Aschner, Michael T. Williams


  • Open Access

    Electroencephalographic and Convulsive Effects of Binge Doses of (+)- Methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4- Methylenedioxymethamphetamine in Rats

    by Devon L. Graham, Nicole R. Herring, Tori L. Schaefer, Katherine D. Holland, Charles V. Vorhees, Michael T. Williams

    Electroencephalographic and Convulsive Effects of Binge Doses of (+)- Methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4- Methylenedioxymethamphetamine in Rats


  • Effects of developmental stress and lead (Pb) on corticosterone after chronic and acute stress, brain monoamines, and blood Pb levels in rats

    by Devon L. Graham, Curtis E. Grace, Amanda A. Braun, Tori L. Schaefer, Matthew R. Skelton, Peter H. Tang, Charles V. Vorhees, Michael T. Williams

    Despite restrictions, exposure to lead (Pb) continues. Moreover, exposure varies and is often higher in lower socioeconomic status (SES) families and remains a significant risk to cognitive development. Stress is another risk factor. Lower SES may be a proxy for stress in humans. When stress and Pb co‐occur, risk may be increased. A few previous experiments have combined Pb with intermittent or acute stress but not with chronic stress. To determine if chronic developmental stress affects outcome in combination with Pb, we tested such effects on growth, organ weight, brain monoamines, and response to an acute stressor. Sprague Dawley rats were gavaged with Pb acetate (1 or 10 mg/kg) or vehicle every other day from postnatal day (P)4–29 and reared in standard or barren cages. Subsets were analyzed at different ages (P11, 19, 29). Chronic stress did not alter blood Pb levels but altered HPA axis response during early development whereas Pb did not. Pb treatment and rearing each altered organ‐to‐body weight ratios, most notably of thymus weights. Both Pb and rearing resulted in age‐ and region‐dependent changes in serotonin and norepinephrine levels and in dopamine and serotonin turnover. The model introduced here may be useful for investigating the interaction of Pb and chronic developmental stress.


  • Open Access

    Comparison of time-dependent effects of (+)-methamphetamine or forced swim on monoamines, corticosterone, glucose, creatine, and creatinine in rats

    by Nicole R Herring, Tori L Schaefer, Peter H Tang, Matthew R Skelton, James P Lucot, Gary A Gudelsky, Charles V Vorhees, Michael T Williams

    Background: Methamphetamine (MA) use is a worldwide problem. Abusers can have cognitive deficits, monoamine reductions, and altered magnetic resonance spectroscopy findings. Animal models have been used to investigate some of these effects, however many of these experiments have not examined the impact of MA on the stress response. For example, numerous studies have demonstrated (+)-MA-induced neurotoxicity and monoamine reductions, however the effects of MA on other markers that may play a role in neurotoxicity or cell energetics such as glucose, corticosterone, and/or creatine have received less attention. In this experiment, the effects of a neurotoxic regimen of (+)-MA (4 doses at 2 h intervals) on brain monoamines, neostriatal GFAP, plasma corticosterone, creatinine, and glucose, and brain and muscle creatine were evaluated 1, 7, 24, and 72 h after the first dose. In order to compare MA's effects with stress, animals were subjected to a forced swim test in a temporal pattern similar to MA administration [i.e., (30 min/session) 4 times at 2 h intervals].Results: MA increased corticosterone from 1–72 h with a peak 1 h after the first treatment, whereas glucose was only increased 1 h post-treatment. Neostriatal and hippocampal monoamines were decreased at 7, 24, and 72 h, with a concurrent increase in GFAP at 72 h. There was no effect of MA on regional brain creatine, however plasma creatinine was increased during the first 24 h and decreased by 72 h. As with MA treatment, forced swim increased corticosterone more than MA initially. Unlike MA, forced swim reduced creatine in the cerebellum with no change in other brain regions while plasma creatinine was decreased at 1 and 7 h. Glucose in plasma was decreased at 7 h.Conclusion: Both MA and forced swim increase demand on energy substrates but in different ways, and MA has persistent effects on corticosterone that are not attributable to stress alone.